BERKELEY, Calif. and VANCOUVER, British Columbia, June 21, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to provide a Corporate Update on its activities and new developments, including positive Phase IIa safety information, discovery of tumor shrinkage mechanism, and patient …

(Accesswire — June 13, 2018) – BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, will be presenting at this year’s MicroCap Conference on June 21st in Toronto, Canada. Dr. Bill Williams, BriaCell’s President and CEO will discuss Bria-IMT™, BriaCell’s lead clinical candidate, its potential in …

BERKELEY, Calif. and VANCOUVER, British Columbia, May 29, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it will publish its clinical findings in the American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings. ASCO’s Annual Meeting, taking place June …

BERKELEY, Calif. and VANCOUVER, British Columbia, May 21, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the publication of the novel mechanism of action of BriaCell’s lead product candidate, Bria-IMT™ in the journal of Frontiers in Immunology, the …

BERKELEY, Calif. and VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Sylvester Comprehensive Cancer Center at the University of Miami is now actively screening and enrolling patients in the ongoing, multicenter, Phase …

– Early data points to safety and early efficacy of Bria-IMT™ in Advanced Stage IV Breast cancer – BERKELEY, Calif. and VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that it has presented …